Bio-Rad Laboratories, Inc. (BIO) Q3 2011 Earnings Results

Bio-Rad Laboratories Beats on EPS, Stock Down 4.38%

Bio-Rad Laboratories reported a positive surprise on EPS, indicating better-than-expected profitability. However, the stock fell by 4.38%, likely due to a lack of revenue details and no guidance for future performance. Investors may be cautious given the absence of specific future projections, which can lead to uncertainty in the stock's direction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.61	N/A	+1.26%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed confidence in the company's strategic direction and resilience. They acknowledged external pressures but remained focused on long-term growth.

Management highlighted strong performance in core segments despite market challenges.

They emphasized ongoing investments in innovation and customer engagement.

Bio-Rad Laboratories Beats on EPS, Stock Down 4.38%

Key numbers

Management commentary

Bio-Rad Laboratories, Inc.

More earnings this week

Bio-Rad Laboratories Beats on EPS, Stock Down 4.38%

Key numbers

Management commentary